Evidence map›Paper›PMID 32652061›Full record

ArticleCell host & microbe2020

Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts.

Kosuke Fujimoto, Yasumasa Kimura, Masaki Shimohigoshi, Takeshi Satoh, Shintaro Sato, Georg Tremmel, Miho Uematsu, Yunosuke Kawaguchi, Yuki Usui, Yoshiko Nakano and 14 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cell host & microbe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 80 citations in OpenAlex.

  1. Review
  2. Article
  3. Journal of microbiology and biotechnology · 2026
    Article
  4. Bacteriophage Therapy AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Efficient Recovery of Complete Gut Viral Genomes by Combined Short- and Long-Read Sequencing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 2 countries.

Kosuke FujimotoDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; Division of Metagenome Medicine, Human Genome Center, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan; Division of Innate Immune Regulation, International Research and Development Center for Mucosal Vaccines, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Yasumasa KimuraDivision of Systems Immunology, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Masaki ShimohigoshiDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Takeshi SatohDivision of Systems Immunology, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Shintaro SatoDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; Mucosal Vaccine Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
Georg TremmelLaboratory of DNA Information Analysis, Human Genome Center, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Miho UematsuDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Yunosuke KawaguchiDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Yuki UsuiDivision of Systems Immunology, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Yoshiko NakanoDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Tetsuya HayashiDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Koji KashimaDivision of Mucosal Immunology, Department of Microbiology and Immunology, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Yoshikazu YukiDivision of Mucosal Immunology, Department of Microbiology and Immunology, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Kiyoshi YamaguchiDivision of Clinical Genome Research, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Yoichi FurukawaDivision of Clinical Genome Research, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Masanori KakutaLaboratory of DNA Information Analysis, Human Genome Center, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Yutaka AkiyamaDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8550, Japan.
Rui YamaguchiLaboratory of DNA Information Analysis, Human Genome Center, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Sheila E CroweDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Peter B ErnstDivision of Gastroenterology, Department of Medicine, CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines, University of California, San Diego, La Jolla, CA 92093, USA; Division of Comparative Pathology and Medicine, Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA; Center for Veterinary Sciences and Comparative Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Satoru MiyanoLaboratory of DNA Information Analysis, Human Genome Center, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Hiroshi KiyonoDivision of Gastroenterology, Department of Medicine, CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines, University of California, San Diego, La Jolla, CA 92093, USA; Division of Comparative Pathology and Medicine, Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA; Department of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Sciences, The University of Tokyo, Tokyo 108-8639, Japan; International Research and Development Center for Mucosal Vaccines, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan.
Seiya ImotoDivision of Health Medical Intelligence, Human Genome Center, The Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan; Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Tokyo 113-8657, Japan. Electronic address: imoto@ims.u-tokyo.ac.jp.
Satoshi UematsuDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; Division of Metagenome Medicine, Human Genome Center, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan; Division of Innate Immune Regulation, International Research and Development Center for Mucosal Vaccines, the Institute of Medical Sciences, the University of Tokyo, Tokyo 108-8639, Japan; Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Tokyo 113-8657, Japan. Electronic address: uematsu.satoshi@med.osaka-cu.ac.jp.
The University of Tokyo · JPOsaka City University · JPUniversity of California, San Diego · USTokyo Institute of Technology · JP

Funding

The Role of the Adenosine Receptor in Th Cell Development and FunctionR01AI079145 · NIAID · UNIVERSITY OF VIRGINIA · PI ERNST, PETER B. · 2010 to 2022
$4.7M
NIAID NIH HHS R01 AI079145
6 · The paper itself

Abstract

The application of bacteriophages (phages) is proposed as a highly specific therapy for intestinal pathobiont elimination. However, the infectious associations between phages and bacteria in the human intestine, which is essential information for the development of phage therapies, have yet to be fully elucidated. Here, we report the intestinal viral microbiomes (viromes), together with bacterial microbiomes (bacteriomes), in 101 healthy Japanese individuals. Based on the genomic sequences of bacteriomes and viromes from the same fecal samples, the host bacteria-phage associations are illustrated for both temperate and virulent phages. To verify the usefulness of the comprehensive host bacteria-phage information, we screened Clostridioides difficile-specific phages and identified antibacterial enzymes whose activity is confirmed both in vitro and in vivo. These comprehensive metagenome analyses reveal not only host bacteria-phage associations in the human intestine but also provide vital information for the development of phage therapies against intestinal pathobionts.

Indexed as

AnimalsAnti-Bacterial AgentsBacteriophagesClostridioides difficileClostridium InfectionsDisease Models, AnimalEndopeptidasesFecesFemaleGastrointestinal MicrobiomeGenome, BacterialGenome, ViralHumansMetagenomeMiceMice, Inbred C57BLAnti-Bacterial AgentsendolysinEndopeptidasesViral ProteinsbacteriomebacteriophageClostridioides difficile infectionCRISPRhost bacteria-phage associationmetagenome analysisprophagevirome

Identifiers

PMID32652061
OpenAlexW3042057078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.